Emotional EatingSatisensNCT07079046
Efficacy of Satisens® in Reducing Emotional Eating
A study testing Intervention 1: Satisens® in people with Emotional Eating and Overweight or Obesity, run by José Enrique de la Rubia Ortí, Ph at 1 site in Spain.
Trial summary
This study evaluates the efficacy of Satisens®, a dietary supplement composed of plant extracts, in reducing emotional eating and sweet cravings in healthy adults. The study will analyze hormonal, neurotransmitter, and inflammatory markers to understand the underlying mechanisms. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Emotional Eating, Overweight or Obesity, Hormonal Changes
- What is being tested?
- Intervention 1: Satisens®
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 84 participants
- Where
- 1 siteSpain
- Study dates
- 15 Sep 2025to 1 Jan 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adults aged 18 to 65 years
- Healthy individuals without chronic diseases
- Able to provide informed consent
Who cannot join
- Pregnant or breastfeeding women
- Individuals taking medications or supplements that may interfere with study variables
- Individuals engaging in more than 3 hours of active exercise per week
Trial locations and contacts
1 site in 1 country.
Spain1 site
Universidad Católica de Valencia San Vicente Mártir - Facultad de Medicina y Ciencias de la Salud
Valencia, Valencia, 46001
About this study
This study evaluates the efficacy of Satisens®, a dietary supplement composed of plant extracts, in reducing emotional eating and sweet cravings in healthy adults. The study will analyze hormonal, neurotransmitter, and inflammatory markers to understand the underlying mechanisms.
Read the detailed description
This study aims to evaluate the efficacy of Satisens®, a dietary supplement composed of lemon verbena (Lippia citriodora), hibiscus (Hibiscus sabdariffa), and saffron (Crocus sativus), in reducing emotional eating and sweet cravings in healthy adults. The supplement is hypothesized to modulate appetite through neuroendocrine and anti-inflammatory mechanisms.
The study is a prospective, longitudinal, mixed-method, analytical, and experimental clinical trial. Participants will be randomly assigned to intervention or placebo groups. The intervention group will receive two capsules of Satisens® daily for 8 weeks, with a subgroup continuing for an additional 4 weeks or switching to placebo. The placebo group will receive identical capsules without active ingredients.
Primary outcomes include changes in emotional eating, appetite, sweet cravings, body weight, BMI, waist circumference, and waist-to-hip ratio. Secondary outcomes include blood levels of appetite-related hormones, neurotransmitters, and inflammatory markers.
Emotional eating will be assessed using validated questionnaires (EEQ, VAS, PFS). Blood samples will be analyzed using chromatography and mass spectrometry techniques. Statistical analysis will include paired t-tests or Wilcoxon tests, Mann-Whitney U tests, correlation analysis, and structural equation modeling.
The study has received ethical approval from the Ethics Committee of the Universidad Católica de Valencia San Vicente Mártir (code: UCV/2024-2025/015) and complies with the Declaration of Helsinki and GDPR regulations.
- Conditions
- Emotional Eating, Overweight or Obesity, Hormonal Changes, Neurotransmitter Agents, Food Cravings, Appetite Regulation
- Being tested
- Intervention 1: Satisens®, Intervention 2: Placebo
- Keywords
- Emotional Eating, Appetite Regulation, Food Craving, Sweet Cravings, Obesity Prevention, Dietary Supplement, Plant Extracts, Lemon Verbena, Hibiscus sabdariffa, Polyphenols, Inflammation, Nutritional Intervention, Clinical Trial, Biomarkers
- Medical subject headings
- Emotional Eating, Overweight, Obesity, Body Weight, Inflammation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Intervention 1: Satisens®Dietary supplement
Also called Satisens®, Plant-based satiety supplement
A dietary supplement composed of lemon verbena (Lippia citriodora), hibiscus (Hibiscus sabdariffa), saffron (Crocus sativus), and carob extract. Administered as 2 capsules daily with breakfast or lunch. Used to modulate appetite, emotional eating, and inflammatory markers.
Intervention 2: PlaceboDietary supplement
Also called Placebo capsule, Sucrose capsule
Identical in appearance to the active supplement. Contains water with sucrose and no active ingredients. Administered as 2 capsules daily with breakfast or lunch.
| Study group | Role | What they receive |
|---|---|---|
| Arm 1: Satisens® 8 Weeks | Experimental | Participants receive 2 capsules of Satisens® daily for 8 weeks. The supplement contains lemon verbena, hibiscus, saffron, and other plant extracts. Capsules are taken with breakfast or lunch. Receives: Dietary Supplement: Intervention 1: Satisens® |
| Arm 1.1: Satisens® 12 Weeks | Experimental | Subgroup of Arm 1 continues with Satisens® for an additional 4 weeks (total 12 weeks). Same dosage and administration as initial 8 weeks. Receives: Dietary Supplement: Intervention 1: Satisens® |
| Arm 1.2: Satisens® 8 Weeks + Placebo 4 Weeks | Experimental | Subgroup of Arm 1 receives Satisens® for 8 weeks followed by placebo for 4 weeks. Placebo capsules are identical in appearance and administration. Receives: Dietary Supplement: Intervention 1: Satisens®; Dietary Supplement: Intervention 2: Placebo |
| Arm 2: Placebo 8 Weeks | Placebo comparator | Participants receive placebo capsules for 8 weeks. Capsules are identical in appearance to Satisens® and contain inert ingredients. Receives: Dietary Supplement: Intervention 2: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Emotional Eating Score (EEQ)
Measured using the Emotional Eating Questionnaire (EEQ) to assess changes in emotional eating behavior.
Scale Range: 0 to 30 Interpretation: Higher scores indicate worse emotional eating behavior (i.e., greater tendency to eat in response to emotions).
Measured: Baseline, Week 8, Week 12
Change in Appetite Score (VAS)
Visual Analog Scale adapted for appetite, including hunger, satiety, fullness, and prospective food consumption.
Scale Range: 0 to 100 for each item Interpretation: Higher scores indicate greater satiety and lower appetite. Therefore, a higher PA score reflects a better outcome in terms of appetite control.
Measured: Baseline, Week 8, Week 12
Change in Sweet Craving (PFS)
Power of Food Scale adapted to sweet foods to assess psychological craving. Scale Range: 1 to 5 per item (typically 15 items total; total score range: 15 to 75) Interpretation: Higher scores indicate greater psychological craving for sweet foods, thus a worse outcome in the context of this study.
Measured: Baseline, Week 8, Week 12
Change in Body Weight
Measured in kilograms (kg) using a calibrated scale with participants in a fasting state.
Unit of Measure: Kilograms (kg) Interpretation: A decrease in weight indicates a better outcome.
Measured: Baseline, Week 8, Week 12
Change in Body Mass Index (BMI)
Calculated as weight (kg) divided by height squared (m²). Unit of Measure: kg/m² Interpretation: A decrease in BMI indicates a better outcome.
Measured: Baseline, Week 8, Week 12
Change in Waist Circumference
Measured in centimeters (cm) at the midpoint between the lower margin of the last palpable rib and the top of the iliac crest.
Unit of Measure: Centimeters (cm) Interpretation: A decrease in waist circumference indicates a better outcome.
Measured: Baseline, Week 8, Week 12
Change in Waist-to-Hip Ratio (WHR)
Calculated as waist circumference divided by hip circumference. Unit of Measure: Ratio (unitless) Interpretation: A decrease in WHR indicates a better outcome.
Measured: Baseline, Week 8, Week 12
Secondary outcomes (7)
Change in Appetite-Related Hormones
Blood levels of different Appetite-Related Hormones
Measured: Baseline, Week 8, Week 12
Change in Neurotransmitter Levels
Blood levels of different Neurotransmitter
Measured: Baseline, Week 8, Week 12
Change in Leptin Levels
Measured in serum using ELISA. Leptin is a hormone secreted by adipocytes that signals satiety to the hypothalamus.
Unit of Measure: ng/mL Interpretation: A decrease in leptin levels (in the context of leptin resistance) may indicate improved sensitivity and better appetite regulation.
Measured: Baseline, Week 8, Week 12
Change in Adiponectin Levels
Measured in serum using ELISA. Adiponectin is an anti-inflammatory adipokine associated with improved metabolic health and satiety.
Unit of Measure: µg/mL Interpretation: An increase in adiponectin levels indicates a better outcome (improved metabolic and inflammatory profile).
Measured: Baseline, Week 8, Week 12
Change in Ghrelin Levels
Measured in serum using ELISA. Ghrelin is known as the "hunger hormone" and stimulates appetite.
Unit of Measure: pg/mL Interpretation: A decrease in ghrelin levels indicates a better outcome (reduced hunger signaling).
Measured: Baseline, Week 8, Week 12
Change in Interleukin-6 (IL-6) Levels
Measured in serum using ELISA (Enzyme-Linked Immunosorbent Assay). Unit of Measure: pg/mL Interpretation: A decrease in IL-6 levels indicates a better outcome (reduced inflammation).
Measured: Baseline, Week 8, Week 12
Change in Tumor Necrosis Factor-alpha (TNF-α) Levels
Measured in serum using ELISA (Enzyme-Linked Immunosorbent Assay). Unit of Measure: pg/mL Interpretation: A decrease in TNF-α levels indicates a better outcome (reduced inflammation).
Measured: Baseline, Week 8, Week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jul 2025
- Study start15 Sep 2025
- Primary completion18 Dec 2025
- Study completion1 Jan 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Emotional EatingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This is a prospective, longitudinal, mixed-method, analytical, and experimental clinical trial. Participants will be randomly assigned to one of three groups: an intervention group receiving Satisens® for 8 weeks, a placebo group, and a subgroup of the intervention group that will either continue with Satisens® or switch to placebo for an additional 4 weeks. The study uses a parallel assignment model to compare the effects of the intervention on emotional eating, appetite, and related biomarkers.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 84 participants (actual)
Sponsor and investigators
- Lead sponsor
- José Enrique de la Rubia Ortí, Ph
- Sponsor type
- University, hospital or other
- Collaborators
- VINABAS FORMULATIONS SL
- Responsible party
- Sponsor-investigator, José Enrique de la Rubia Ortí, Ph, Fundación Universidad Católica de Valencia San Vicente Mártir
- Investigators
- José Enrique Dr. de la Rubia Ortí, PhD in Pharmacy, Principal investigator, Universidad Católica de Valencia San Vicente MártirGonzalo Mariscal Ruiz-Rico, Principal investigator, Universidad Católica de Valencia San Vicente MártirAna Belén Carriquí Suárez, Study director, Facultad de Medicina y Ciencias de la Salud, Universidad Católica de Valencia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07079046
- Sponsor's protocol ID
- UCV/2024-2025/015
- Acronym
- Satisens
- Status last verified
- Jul 2025
- First submitted
- 18 Jun 2025
- Last updated
- 22 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data (IPD) will not be shared due to institutional data protection policies and the nature of the study, which involves sensitive health-related and psychological information. Data will be handled in compliance with the EU General Data Protection Regulation (GDPR) and Spanish data protection laws, and will remain confidential and accessible only to the research team.
Study at a glance
From the registry record, last updated by the sponsor on 22 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of Satisens® in Reducing Emotional Eating
- ClinicalTrials.gov ID
- NCT07079046
- Acronym / sponsor ID
- Satisens / UCV/2024-2025/015
- Conditions
- Emotional Eating, Overweight or Obesity, Hormonal Changes, Neurotransmitter Agents, Food Cravings, Appetite Regulation
- Keywords
- Emotional Eating, Appetite Regulation, Food Craving, Sweet Cravings, Obesity Prevention, Dietary Supplement, Plant Extracts, Lemon Verbena
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 84 participants (actual)
- Lead sponsor
- José Enrique de la Rubia Ortí, PhUniversity, hospital or other
- Collaborators
- VINABAS FORMULATIONS SL
- Study start
- 15 Sep 2025 (actual)
- Primary completion
- 18 Dec 2025 (actual)
- Study completion
- 1 Jan 2026 (actual)
- First posted
- 22 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluates the efficacy of Satisens®, a dietary supplement composed of plant extracts, in reducing emotional eating and sweet cravings in healthy adults. The study will analyze hormonal, neurotransmitter, and inflammatory markers to understand the underlying mechanisms.
Detailed description
This study aims to evaluate the efficacy of Satisens®, a dietary supplement composed of lemon verbena (Lippia citriodora), hibiscus (Hibiscus sabdariffa), and saffron (Crocus sativus), in reducing emotional eating and sweet cravings in healthy adults. The supplement is hypothesized to modulate appetite through neuroendocrine and anti-inflammatory mechanisms.
The study is a prospective, longitudinal, mixed-method, analytical, and experimental clinical trial. Participants will be randomly assigned to intervention or placebo groups. The intervention group will receive two capsules of Satisens® daily for 8 weeks, with a subgroup continuing for an additional 4 weeks or switching to placebo. The placebo group will receive identical capsules without active ingredients.
Primary outcomes include changes in emotional eating, appetite, sweet cravings, body weight, BMI, waist circumference, and waist-to-hip ratio. Secondary outcomes include blood levels of appetite-related hormones, neurotransmitters, and inflammatory markers.
Emotional eating will be assessed using validated questionnaires (EEQ, VAS, PFS). Blood samples will be analyzed using chromatography and mass spectrometry techniques. Statistical analysis will include paired t-tests or Wilcoxon tests, Mann-Whitney U tests, correlation analysis, and structural equation modeling.
The study has received ethical approval from the Ethics Committee of the Universidad Católica de Valencia San Vicente Mártir (code: UCV/2024-2025/015) and complies with the Declaration of Helsinki and GDPR regulations.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 4
- Model description
- This is a prospective, longitudinal, mixed-method, analytical, and experimental clinical trial. Participants will be randomly assigned to one of three groups: an intervention group receiving Satisens® for 8 weeks, a placebo group, and a subgroup of the intervention group that will either continue with Satisens® or switch to placebo for an additional 4 weeks. The study uses a parallel assignment model to compare the effects of the intervention on emotional eating, appetite, and related biomarkers.
| Arm | Type | Receives |
|---|---|---|
| Arm 1: Satisens® 8 Weeks | Experimental | Dietary Supplement: Intervention 1: Satisens®Participants receive 2 capsules of Satisens® daily for 8 weeks. The supplement contains lemon verbena, hibiscus, saffron, and other plant extracts. Capsules are taken with breakfast or lunch. |
| Arm 1.1: Satisens® 12 Weeks | Experimental | Dietary Supplement: Intervention 1: Satisens®Subgroup of Arm 1 continues with Satisens® for an additional 4 weeks (total 12 weeks). Same dosage and administration as initial 8 weeks. |
| Arm 1.2: Satisens® 8 Weeks + Placebo 4 Weeks | Experimental | Dietary Supplement: Intervention 1: Satisens®, Dietary Supplement: Intervention 2: PlaceboSubgroup of Arm 1 receives Satisens® for 8 weeks followed by placebo for 4 weeks. Placebo capsules are identical in appearance and administration. |
| Arm 2: Placebo 8 Weeks | Placebo comparator | Dietary Supplement: Intervention 2: PlaceboParticipants receive placebo capsules for 8 weeks. Capsules are identical in appearance to Satisens® and contain inert ingredients. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Adults aged 18 to 65 years
- Healthy individuals without chronic diseases
- Able to provide informed consent
Key exclusion criteria (3 listed)
- Pregnant or breastfeeding women
- Individuals taking medications or supplements that may interfere with study variables
- Individuals engaging in more than 3 hours of active exercise per week
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Intervention 1: Satisens®Also: Satisens®, Plant-based satiety supplementA dietary supplement composed of lemon verbena (Lippia citriodora), hibiscus (Hibiscus sabdariffa), saffron (Crocus sativus), and carob extract. Administered as 2 capsules daily with breakfast or lunch. Used to modulate appetite, emotional eating, and inflammatory markers. | Dietary supplement | Arm 1.1: Satisens® 12 Weeks, Arm 1.2: Satisens® 8 Weeks + Placebo 4 Weeks, Arm 1: Satisens® 8 Weeks |
| Intervention 2: PlaceboAlso: Placebo capsule, Sucrose capsuleIdentical in appearance to the active supplement. Contains water with sucrose and no active ingredients. Administered as 2 capsules daily with breakfast or lunch. | Dietary supplement | Arm 1.2: Satisens® 8 Weeks + Placebo 4 Weeks, Arm 2: Placebo 8 Weeks |
Primary outcome
Change in Emotional Eating Score (EEQ)
Time frame: Baseline, Week 8, Week 12
Measured using the Emotional Eating Questionnaire (EEQ) to assess changes in emotional eating behavior. Scale Range: 0 to 30 Interpretation: Higher scores indicate worse emotional eating behavior (i.e., greater tendency to eat in response to emotions).
Change in Appetite Score (VAS)
Time frame: Baseline, Week 8, Week 12
Visual Analog Scale adapted for appetite, including hunger, satiety, fullness, and prospective food consumption. Scale Range: 0 to 100 for each item Interpretation: Higher scores indicate greater satiety and lower appetite. Therefore, a higher PA score reflects a better outcome in terms of appetite control.
Change in Sweet Craving (PFS)
Time frame: Baseline, Week 8, Week 12
Power of Food Scale adapted to sweet foods to assess psychological craving. Scale Range: 1 to 5 per item (typically 15 items total; total score range: 15 to 75) Interpretation: Higher scores indicate greater psychological craving for sweet foods, thus a worse outcome in the context of this study.
Change in Body Weight
Time frame: Baseline, Week 8, Week 12
Measured in kilograms (kg) using a calibrated scale with participants in a fasting state. Unit of Measure: Kilograms (kg) Interpretation: A decrease in weight indicates a better outcome.
Change in Body Mass Index (BMI)
Time frame: Baseline, Week 8, Week 12
Calculated as weight (kg) divided by height squared (m²). Unit of Measure: kg/m² Interpretation: A decrease in BMI indicates a better outcome.
Change in Waist Circumference
Time frame: Baseline, Week 8, Week 12
Measured in centimeters (cm) at the midpoint between the lower margin of the last palpable rib and the top of the iliac crest. Unit of Measure: Centimeters (cm) Interpretation: A decrease in waist circumference indicates a better outcome.
Change in Waist-to-Hip Ratio (WHR)
Time frame: Baseline, Week 8, Week 12
Calculated as waist circumference divided by hip circumference. Unit of Measure: Ratio (unitless) Interpretation: A decrease in WHR indicates a better outcome.
7 secondary outcomes
Change in Appetite-Related Hormones
Time frame: Baseline, Week 8, Week 12
Change in Neurotransmitter Levels
Time frame: Baseline, Week 8, Week 12
Change in Leptin Levels
Time frame: Baseline, Week 8, Week 12
Change in Adiponectin Levels
Time frame: Baseline, Week 8, Week 12
Change in Ghrelin Levels
Time frame: Baseline, Week 8, Week 12
Change in Interleukin-6 (IL-6) Levels
Time frame: Baseline, Week 8, Week 12
Change in Tumor Necrosis Factor-alpha (TNF-α) Levels
Time frame: Baseline, Week 8, Week 12
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jun 2026.
- Official website of Universidad Católica de Valencia San Vicente Mártir, where the study is being conducted.Link provided by the sponsor.
- Official profile of Dr. José Enrique de la Rubia Ortí and his research group "El estrés y la enfermedad" at the Catholic University of Valencia. Includes academic background, research lines, and scientific publications.Link provided by the sponsor.
- Official website of IVB Wellness Lab, the company collaborating on the clinical trial. Founded by Dr. Isabel Viña Bas, the company develops scientifically backed nutritional supplements, including SatiSens.Link provided by the sponsor.
- Official news release from the Catholic University of Valencia announcing the clinical trial on a saffron-based supplement aimed at reducing sweet cravings and emotional eating.Link provided by the sponsor.
- Media article discussing the potential of the saffron-based supplement SatiSens as a natural alternative to appetite suppressants, highlighting its role in the clinical trial.Link provided by the sponsor.
- Individual participant dataSharing planned: No. Individual participant data (IPD) will not be shared due to institutional data protection policies and the nature of the study, which involves sensitive health-related and psychological information. Data will be handled in compliance with the EU General Data Protection Regulation (GDPR) and Spanish data protection laws, and will remain confidential and accessible only to the research team.
Related trials for Emotional Eating
Recruiting
Momentary Coping Prompts and Hair Steroids in College Students
Emotional Regulation, Alcohol Drinking in College
Recruiting
Effects of a Mindful Self-Compassion Intervention on Psychological Adjustment in Breast Cancer Survivors
Breast Cancer
Recruiting
Body-Based and Mind-Based Regulation in Overweight and Obese Women
Overweight and/or Obesity
Recruiting
Just-in-Time Coping Prompts for Reactive Digital Behavior in College Students
Emotional Regulation, Alcohol Drinking in College
Recruiting
Readiness and Progress in Emotion Regulation Therapy
Rumination, Worry
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
José Enrique Dr. de la Rubia Ortí, PhD in Pharmacy principal investigator
Universidad Católica de Valencia San Vicente Mártir
Gonzalo Mariscal Ruiz-Rico principal investigator
Universidad Católica de Valencia San Vicente Mártir
Ana Belén Carriquí Suárez study director
Facultad de Medicina y Ciencias de la Salud, Universidad Católica de Valencia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Intervention 1: Satisens® in people with Emotional Eating and Overweight or Obesity, run by José Enrique de la Rubia Ortí, Ph at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Emotional Eating Score (EEQ) (time frame: Baseline, Week 8, Week 12). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jun 2026.